ArticleNeuropsychiatric disease and treatment2026
Comparison of Neurocognitive Effects of Blonanserin, Olanzapine, Aripiprazole, and Risperidone in Drug-Naïve First-Episode Schizophrenia.
Article in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neurocognitive deficits are a core feature of schizophrenia. The specific impact of antipsychotics on neurocognitive function in drug-naïve first-episode schizophrenia (FES) remains unclear, especially for newer agents like blonanserin. This study compared the neurocognitive effects of blonanserin, olanzapine, aripiprazole, and risperidone during the first 6 months of treatment in FES patients. Study Design: Data were derived from two clinical trials in which FES patients received initial treatment with blonanserin, olanzapine, aripiprazole, or risperidone. Neurocognitive function was assessed at baseline and 6 months using multiple measures. Paired t-tests evaluated within-group changes, and repeated measures ANOVA examined differential effects across groups. Study Results: Of 594 recruited patients, 294 completed follow-up. All four groups showed comparable improvements in processing speed and working memory. A significant group-by-time interaction was observed for verbal ( Conclusion: Initial antipsychotic treatment in drug-naïve FES patients is associated with neurocognitive benefits, particularly in processing speed and working memory. Furthermore, blonanserin may offer advantages in ameliorating learning and memory deficits compared to risperidone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.